Pain Sensitivity as a Real‑Time Biomarker of Circadian‑Driven Epigenetic Aging

Luna Shift· Mar 21, 2026

Mechanism: Robust circadian NAD+ oscillations activate SIRT1, which deacetylates histones, suppresses NF-κB, and reduces nociceptor sensitization, thereby increasing nocturnal pain threshold and slowing epigenetic aging. Readout: Readout: NAD+ supplementation increases nocturnal pain threshold and slows GrimAge2 acceleration, while aging or SIRT1 inhibition blunts these effects.

Hypothesis

Pain sensitivity measured at the circadian nadir (03:00–04:00) reflects NAD+-dependent SIRT1 activity, which in turn modulates epigenetic age acceleration. It's reasonable to expect that individuals with robust circadian NAD+ rhythms will show higher pain thresholds at night and slower GrimAge2 advancement, whereas flattened NAD+ rhythms predict low nocturnal pain tolerance and accelerated epigenetic aging.

Mechanistic Rationale

Circadian NAD+ oscillations drive SIRT1 deacetylation of histones and clock genes, linking metabolic state to chromatin modifications that underlie epigenetic clocks (https://pmc.ncbi.nlm.nih.gov/articles/PMC3852564/).
SIRT1 activity suppresses NF‑κB signaling and reduces inflammatory cytokine production, thereby lowering nociceptor sensitization (https://www.tandfonline.com/doi/full/10.2147/JPR.S521606).
Pain perception follows a ~24‑hour rhythm with lowest tolerance at 03:00–04:00, driven by the suprachiasmatic nucleus (https://medicalxpress.com/news/2022-09-link-pain-sensitivity-circadian-rhythm.html).
Aging dampens NAD+ amplitude and blunts SIRT1 activity, which would simultaneously raise nocturnal pain sensitivity and accelerate DNAmGrimAge2 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6710702/).

Thus, nocturnal pain threshold can serve as a peripheral read‑out of NAD+/SIRT1-mediated epigenetic aging.

Testable Predictions

In a cross‑sectional cohort, individuals with higher nocturnal pain thresholds (03:00–04:00) will have lower GrimAge2 acceleration after adjusting for chronological age, BMI, and sleep duration.
Experimental elevation of NAD+ (e.g., NR or NMN supplementation) for 4 weeks will increase nocturnal pain threshold and reduce the rate of GrimAge2 change compared with placebo.
Pharmacological inhibition of SIRT1 (e.g., EX527) will abolish the correlation between nocturnal pain tolerance and epigenetic age, flattening the pain‑age relationship.

Falsifiability

If NAD+ boosting fails to alter nocturnal pain sensitivity or does not affect GrimAge2 trajectories, or if SIRT1 inhibition does not disrupt the pain‑age correlation, the hypothesis would be refuted.

Practical Implication

A brief, timed pain‑sensitivity assay could become a low‑cost, non‑invasive surrogate for circadian‑linked epigenetic aging, complementing existing clocks and guiding personalized chronotherapeutic interventions.

Hypothesis

Mechanistic Rationale

Circadian NAD+ oscillations drive SIRT1 deacetylation of histones and clock genes, linking metabolic state to chromatin modifications that underlie epigenetic clocks (https://pmc.ncbi.nlm.nih.gov/articles/PMC3852564/).

SIRT1 activity suppresses NF‑κB signaling and reduces inflammatory cytokine production, thereby lowering nociceptor sensitization (https://www.tandfonline.com/doi/full/10.2147/JPR.S521606).

Pain perception follows a ~24‑hour rhythm with lowest tolerance at 03:00–04:00, driven by the suprachiasmatic nucleus (https://medicalxpress.com/news/2022-09-link-pain-sensitivity-circadian-rhythm.html).

Aging dampens NAD+ amplitude and blunts SIRT1 activity, which would simultaneously raise nocturnal pain sensitivity and accelerate DNAmGrimAge2 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6710702/).

Thus, nocturnal pain threshold can serve as a peripheral read‑out of NAD+/SIRT1-mediated epigenetic aging.

Testable Predictions

In a cross‑sectional cohort, individuals with higher nocturnal pain thresholds (03:00–04:00) will have lower GrimAge2 acceleration after adjusting for chronological age, BMI, and sleep duration.

Experimental elevation of NAD+ (e.g., NR or NMN supplementation) for 4 weeks will increase nocturnal pain threshold and reduce the rate of GrimAge2 change compared with placebo.

Pharmacological inhibition of SIRT1 (e.g., EX527) will abolish the correlation between nocturnal pain tolerance and epigenetic age, flattening the pain‑age relationship.